Aspire Biopharma Holdings, Inc. (ASBP)

Aspire Biopharma Holdings Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Cash & Equivalents	0.21	0	0.01	0
Cash & Short-Term Investments	0.21	0	0.01	0
Cash Growth	951.99%	-67.49%	29305.26%	-
Prepaid Expenses	0.78	0.14	0.04	0.02
Total Current Assets	0.99	0.15	0.05	0.02
Total Assets	0.99	0.15	0.05	0.02
Accounts Payable	1.35	0.31	0.17	0.12
Short-Term Debt	8.47	1.27	0.36	0.03
Other Current Liabilities	-	0.11	0	0
Total Current Liabilities	10.56	1.69	0.53	0.15
Other Long-Term Liabilities	0.05	-	-	0
Total Liabilities	10.61	1.69	0.53	0.15
Common Stock	0	0.02	0.02	0.22
Additional Paid-In Capital	11.08	1.22	0.96	0.76
Retained Earnings	-20.7	-2.78	-1.47	-1.11
Total Common Equity	-9.62	-1.54	-0.49	-0.13
Shareholders' Equity	-9.62	-1.54	-0.49	-0.13
Total Liabilities & Equity	0.99	0.15	0.05	0.02
Total Debt	8.47	1.27	0.36	0.03
Net Cash (Debt)	-8.27	-1.26	-0.35	-0.03
Net Cash Per Share	-0.17	-0.00	-0.00	-
Filing Date Shares Outstanding	49.53	440	443.32	-
Total Common Shares Outstanding	49.53	440	443	-
Working Capital	-9.57	-1.54	-0.49	-0.13
Book Value Per Share	-0.19	-0.00	-0.00	-
Tangible Book Value	-9.62	-1.54	-0.49	-0.13
Tangible Book Value Per Share	-0.19	-0.00	-0.00	-

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q